Ileocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study.
Adult
Biopsy
Case-Control Studies
Clostridiales
/ genetics
Colon
/ diagnostic imaging
DNA, Bacterial
/ isolation & purification
Feces
/ microbiology
Female
Gastrointestinal Microbiome
/ genetics
Humans
Ileum
/ diagnostic imaging
Intestinal Mucosa
/ diagnostic imaging
Irritable Bowel Syndrome
/ diagnosis
Male
Mast Cells
/ immunology
Middle Aged
Paneth Cells
/ immunology
RNA, Ribosomal, 16S
/ genetics
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
22 12 2020
22 12 2020
Historique:
received:
27
07
2020
accepted:
23
11
2020
entrez:
19
1
2021
pubmed:
20
1
2021
medline:
9
9
2021
Statut:
epublish
Résumé
Histopathological alterations in the ileum and colon in irritable bowel syndrome (IBS) are controversial, and normal values are poorly established. We hypothesized that changes in mucosal immune cells characterize IBS and key changes in immune composition are associated with the mucosa-associated microbiota (MaM). A nested case-control study (48 IBS and 106 controls included) from 745 colonoscopy participants in a random population sample. Intraepithelial lymphocytes (IELs)/100 enterocytes and eosinophils/5 nonoverlapping high-power fields counted; mast cells identified by immunocytochemistry (CD117)/5 high-power fields. Paneth cells quantified per 5 crypts. 16S rRNA gene amplicon sequencing performed on available sigmoid MaM, n = 55 and fecal microbiota, n = 20. Microbiota profiles compared between samples with high and low IEL counts. IBS had increased IELs in the terminal ileum (relative risk ratio = 1.70, 95% confidence interval 1.08-2.76, P = 0.022 adjusted for age, sex, and smoking). Cecal IELs were increased in IBS-diarrhea (relative risk ratio = 2.03, 95% confidence interval 1.13-3.63, P = 0.017). No difference was observed in alpha diversity of MaM or fecal microbiota based on IEL count. There was no difference in beta diversity of the MaM according to IEL count in the terminal ileal (TI) (P = 0.079). High TI IEL counts associated with a significant expansion of the genus Blautia (P = 0.024) and unclassified Clostridiales (P = 0.036) in colon MaM. A modest but significant increase in IELs was observed in IBS vs. controls in a population-based setting. Subtle TI and cecal inflammation may play a pathogenic role in IBS but needs confirmation. Modest but discernible differences in the colonic MaM were seen according to TI IEL count but not IBS status.
Identifiants
pubmed: 33464728
doi: 10.14309/ctg.0000000000000296
pii: 01720094-202101000-00010
pmc: PMC8345925
doi:
Substances chimiques
DNA, Bacterial
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00296Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):133-146
pubmed: 28404070
Neurogastroenterol Motil. 2018 Jan;30(1):
pubmed: 28851005
Gastroenterol Res Pract. 2016;2016:2031480
pubmed: 28115927
Bioinformatics. 2014 Nov 1;30(21):3123-4
pubmed: 25061070
Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83
pubmed: 17686660
Am J Gastroenterol. 2017 May;112(5):775-784
pubmed: 28323273
Gastroenterology. 2007 Jan;132(1):26-37
pubmed: 17241857
Pathol Res Pract. 2011 Sep 15;207(9):538-44
pubmed: 21940106
N Engl J Med. 2017 Jun 29;376(26):2566-2578
pubmed: 28657875
Front Immunol. 2019 Mar 11;10:277
pubmed: 30915065
United European Gastroenterol J. 2017 Oct;5(6):887-897
pubmed: 29026603
Microbiome. 2017 May 1;5(1):49
pubmed: 28457228
EClinicalMedicine. 2020 Jul 15;25:100465
pubmed: 32954237
Gastroenterology. 2010 Jul;139(1):112-9
pubmed: 20398668
Gastroenterology. 2019 Jul;157(1):109-118.e5
pubmed: 31100380
Eur J Gastroenterol Hepatol. 2014 Mar;26(3):268-75
pubmed: 24384686
Clin Gastroenterol Hepatol. 2019 Mar;17(4):682-690.e3
pubmed: 30138736
Dig Dis Sci. 1993 Sep;38(9):1590-5
pubmed: 8359068
United European Gastroenterol J. 2020 Apr;8(3):284-292
pubmed: 32213021
Am J Clin Pathol. 2007 May;127(5):816-9
pubmed: 17439842
J Neurogastroenterol Motil. 2019 Apr 30;25(2):212-221
pubmed: 30827070
Am J Gastroenterol. 2018 Jul;113(7):1036-1044
pubmed: 29915405
JCI Insight. 2016 Jun 2;1(8):e86907
pubmed: 27699268
Neurogastroenterol Motil. 2019 Oct;31(10):e13576
pubmed: 30790378
Gut. 2010 Sep;59(9):1213-21
pubmed: 20650926
Gastroenterology. 2002 Jun;122(7):1778-83
pubmed: 12055584
Aliment Pharmacol Ther. 2014 Aug;40(3):288-97
pubmed: 24943095
Gastroenterology. 2007 Mar;132(3):913-20
pubmed: 17383420
PLoS One. 2011;6(8):e22547
pubmed: 21829632
Am J Gastroenterol. 2012 Feb;107(2):262-72
pubmed: 22158028
Hum Pathol. 2015 Feb;46(2):277-83
pubmed: 25540866
J Immunol. 2018 Jul 1;201(1):230-242
pubmed: 29794015
Am J Gastroenterol. 2019 Mar;114(3):429-436
pubmed: 30839392
Dig Dis Sci. 2019 Mar;64(3):832-837
pubmed: 30478768
Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1071-5
pubmed: 16148552
Am J Gastroenterol. 2012 May;107(5):715-26
pubmed: 22488080
Aliment Pharmacol Ther. 2009 Apr 1;29(7):765-73
pubmed: 19183150
Gut. 2020 Jun;69(6):1076-1084
pubmed: 31601615
BMC Nutr. 2020 Sep 18;6:47
pubmed: 32963797
Gut. 2017 Sep;66(9):1537-1538
pubmed: 28082316
Eur J Clin Invest. 2015 Dec;45(12):1350-9
pubmed: 26444549
Gut. 2017 May;66(5):978-979
pubmed: 27473415
Nature. 2017 Nov 16;551(7680):333-339
pubmed: 29144463